Oramed Pharmaceuticals Inc.
ORMP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | – | – |
| Gross Profit | -$0 | -$0 | $0 | -$0 |
| % Margin | – | – | 0.7% | – |
| EBITDA | $0 | $0 | -$0 | -$0 |
| % Margin | – | – | -223.5% | – |
| Net Income | $0 | $0 | -$0 | -$0 |
| % Margin | – | – | -382.1% | – |
| EPS Diluted | 1.13 | 0.31 | -0.19 | -0.26 |
| % Growth | 264.5% | 263.2% | 26.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |